OpenAI adds GPT-Rosalind Discovery to pricing list
OpenAI quietly added a new life sciences model, GPT-Rosalind Discovery, to its API pricing table without a formal announcement or blog post, according to ZDNet Korea.
Some disagreement beneath a largely shared set of facts.
Argon Synthesis
IncludedOpenAI quietly added a new life sciences model, GPT-Rosalind Discovery, to its API pricing table without a formal announcement or blog post, according to ZDNet Korea. The model carries the same pricing as the existing GPT-Rosalind Research ($5 per million input tokens, $25 per million output tokens). The name suggests it is designed for drug candidate discovery, though OpenAI has not disclosed its specific use cases or context window size. Separately, OpenAI announced the Rosalind Academic Plan, offering eligible academic labs sponsored access to GPT-Rosalind tools for life sciences research.
Where they diverge
ZDNet Korea focused on the undisclosed addition to the pricing table and the lack of official documentation; OpenAI's announcement emphasized the academic access initiative. The two developments appear related but were communicated through different channels and timelines, with no explicit connection stated by OpenAI.
This synthesis is AI-generated by Argon from the listed sources. It may summarise inaccurately or miss nuance — rely on the original articles for specifics. Read more about Argon's crawler policy.
1 subject in this story
Open any player to see how outlets across the spectrum tend to cover it.
Aggregate substance
2 sources- SensSensationalism
- 6.0
- SpecSpecificity
- 5.5
- CorrCorroboration
- 3.5
- NovNovelty
- 5.0
- IndIndependence
- 3.0
Sources spread by 25 pts
Coverage map
2 sourcesYou're seeing this mostly through a Neutral · ZDNet Korea lens.
No coverage from: UK · EU · Rest
Developing story
How the sources framed it
The same story, grouped by the stance each outlet took.